Shanghai Kehua Bio-Engineering Co Ltd (SHE:002022) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Kehua Bio-Engineering Co Ltd (002022)
Shanghai Kehua Bio-Engineering Co Ltd (SHE:002022) has a market capitalization of $449.34 Million (CN¥3.07 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #13108 globally and #4119 in its home market, demonstrating a 3.29% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Kehua Bio-Engineering Co Ltd's stock price CN¥5.97 by its total outstanding shares 514350669 (514.35 Million). Review Shanghai Kehua Bio-Engineering Co Ltd (002022) financial obligations to assess the company's total debt and financial obligations.
Shanghai Kehua Bio-Engineering Co Ltd Market Cap History: 2015 to 2026
Shanghai Kehua Bio-Engineering Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.98 Billion to $449.34 Million (-12.11% CAGR).
Shanghai Kehua Bio-Engineering Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Kehua Bio-Engineering Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.27x
Shanghai Kehua Bio-Engineering Co Ltd's market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.98 Billion | $1.16 Billion | $210.62 Million | 1.71x | 9.41x |
| 2016 | $1.37 Billion | $1.40 Billion | $232.40 Million | 0.98x | 5.89x |
| 2017 | $939.55 Million | $1.59 Billion | $217.76 Million | 0.59x | 4.31x |
| 2018 | $650.37 Million | $1.99 Billion | $207.78 Million | 0.33x | 3.13x |
| 2019 | $815.14 Million | $2.41 Billion | $202.48 Million | 0.34x | 4.03x |
| 2020 | $1.08 Billion | $4.16 Billion | $675.36 Million | 0.26x | 1.60x |
| 2021 | $1.05 Billion | $4.85 Billion | $850.41 Million | 0.22x | 1.24x |
| 2022 | $885.24 Million | $6.97 Billion | $971.56 Million | 0.13x | 0.91x |
| 2023 | $856.52 Million | $2.43 Billion | -$234.01 Million | 0.35x | N/A |
| 2024 | $474.93 Million | $1.76 Billion | -$640.60 Million | 0.27x | N/A |
Competitor Companies of 002022 by Market Capitalization
Companies near Shanghai Kehua Bio-Engineering Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Shanghai Kehua Bio-Engineering Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Shanghai Kehua Bio-Engineering Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Kehua Bio-Engineering Co Ltd's market cap moved from $1.98 Billion to $ 449.34 Million, with a yearly change of -12.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥449.34 Million | +0.51% |
| 2025 | CN¥447.08 Million | -5.86% |
| 2024 | CN¥474.93 Million | -44.55% |
| 2023 | CN¥856.52 Million | -3.24% |
| 2022 | CN¥885.24 Million | -15.98% |
| 2021 | CN¥1.05 Billion | -2.38% |
| 2020 | CN¥1.08 Billion | +32.40% |
| 2019 | CN¥815.14 Million | +25.34% |
| 2018 | CN¥650.37 Million | -30.78% |
| 2017 | CN¥939.55 Million | -31.41% |
| 2016 | CN¥1.37 Billion | -30.89% |
| 2015 | CN¥1.98 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Shanghai Kehua Bio-Engineering Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $449.34 Million USD |
| MoneyControl | $449.34 Million USD |
| MarketWatch | $449.34 Million USD |
| marketcap.company | $449.34 Million USD |
| Reuters | $449.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more